Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Abbott's XIENCE V Shows Outstanding Two-Year Clinical Results Versus TAXUS in Key Safety and Efficacy Measures in SPIRIT IV Trial
Abbott's XIENCE V Shows Outstanding Two-Year Clinical Results Versus TAXUS in Key Safety and Efficacy Measures in SPIRIT IV Trial
Abbott's XIENCE V Shows Outstanding Two-Year Clinical Results Versus TAXUS in Key Safety and Efficacy Measures in SPIRIT IV Trial
Submitted by
admin
on September 24, 2010 - 12:07pm
Source:
Mass Device
News Tags:
Abbott Laboratories
Xience
Taxus
drug eluting stents
Headline:
Abbott's XIENCE V Shows Outstanding Two-Year Clinical Results Versus TAXUS in Key Safety and Efficacy Measures in SPIRIT IV Trial
Do Not Allow Advertisers to Use My Personal information
